A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03910660 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 10, 2019
Last Update Posted : May 23, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Prostate Cancer Neuroendocrine Tumors Small Cell Carcinoma | Drug: BXCL701 plus Pembrolizumab Drug: BXCL701 monotherapy | Phase 1 Phase 2 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 98 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype |
| Actual Study Start Date : | February 12, 2019 |
| Estimated Primary Completion Date : | October 2023 |
| Estimated Study Completion Date : | December 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Phase 1b
Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. 3 patients will be treated initially with 0.4 mg BXCL701 plus PEMBRO: If there are no DLTs, the dose of BXCL701 will be escalated to 0.6 mg in the next cohort. If ≥1/3 of patients has a DLT in Cycle 1, either 3 patients (if 1 experience a DLT) or 6 to 9 patients (if 2 or 3 experiences a DLT) will be added at the 0.4 mg dose. At the 0.4mg dose: If <1/3 of the patients experience a DLT, consideration will be given to dose to 0.6 mg BXCL701 plus PEMBRO. If 1/3 of the patients experience a DLT, the Phase 2a can commence. If >1/3 of the patients experience a DLT, a discussion will be held as to how to proceed. Following 0.6 mg dose. If there are no DLTs, the Phase 2a can commence. If ≥1/3 patients have a DLT in Cycle 1, after a discussion, 6 to 9 patients will be added at the 0.6 mg dose. For this cohort of 6 to 9 patients: If </=1/3 of the patients experience a DLT, the Phase 2a can commence |
Drug: BXCL701 plus Pembrolizumab
BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration. BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set. BXCL701 should not be taken on an empty stomach. On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day. The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle. Other Name: BXCL701 plus Pembro |
|
Phase 2a
After assessment of the safety and confirmation of the BXCL701/+PEMBRO dose schedule to be used in the subsequent stage, the Phase 2a will begin. Eligible patients will receive BXCL701 QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.
|
Drug: BXCL701 plus Pembrolizumab
BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration. BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set. BXCL701 should not be taken on an empty stomach. On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day. The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle. Other Name: BXCL701 plus Pembro |
|
Phase 2b combination
Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive: • Combination therapy of BXCL701 on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 of every 21 days. |
Drug: BXCL701 plus Pembrolizumab
BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration. BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set. BXCL701 should not be taken on an empty stomach. On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day. The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle. Other Name: BXCL701 plus Pembro |
|
Phase 2b monotherapy
Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:
|
Drug: BXCL701 monotherapy
BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration. BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set. BXCL701 should not be taken on an empty stomach. On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day. Other Name: BXCL701 |
- Phase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBRO [ Time Frame: up to 36 months ]Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; circulating tumor cell (CTC) conversion from >5/7.5 mL to <5/7.5 mL per Veridex assay; and 50% or greater prostate-specific antigen (PSA) decline from baseline.
- Phase 2b: Evaluate response rates in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapy [ Time Frame: up to 36 months ]To evaluate the response rates, defined by RECIST 1.1 criteria, by histologic subtype in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapy.
- Phase 2a: Estimate the median radiographic progression-free survival (rPFS) of the combination of BXCL701 and PEMBRO in Cohort A and B [ Time Frame: up to 36 months ]The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro determined by radiographic evidence.
- Phase 2a: Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in Cohort A and B. [ Time Frame: up to 36 months ]The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro
- Phase 2a: Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in Cohort A and B. [ Time Frame: up to 36 months ]The median time frame with overall survival with the use of BXCL701 in combination with Pembro
- Phase 2a: Estimate the median duration of response (DOR) of the combination of BXCL701 and PEMBRO in Cohort A and B. [ Time Frame: up to 36 months ]The timeframe in which the tumor reacts to BXCL701 in combination with Pembro
- Phase 2a: Determine the risk profile of the use of BXCL701 in combination with PEMBRO. [ Time Frame: up to 36 months ]Determines the frequency and severity of known and unknown adverse events with the use of BXCL701 in combination with Pembro
- Phase 2a: Assess population pK of BXCL701 [ Time Frame: Up to 36 months ]To assess the population pharmacokinetics of BXCL701 using sparse pharmacokinetic sampling.
- Phase 2a: Assess pharmacodynamic profile of BXCL701 and Pembro [ Time Frame: Up to 36 months ]To assess the pharmacodynamic profile of the combination of BXCL701 and PEMBRO by measuring relevant effects on those cytokines previously shown to be modulated by BXCL701 in humans.
- Phase 2b: Estimate the CRR, OS, duration response, rPFS and PSA PFS of the BXCL701+Pembro. [ Time Frame: Up to 36 months ]
To estimate the CRR, OS, duration of response, rPFS, and PSA PFS of the BXCL701 + PEMBRO combination and monotherapy in Cohort A and B, respectively. Composite response rate is defined as achieving 1 or more of the following:
- Objective response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- 50% or greater PSA decline from baseline.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All patients must satisfy the following inclusion and exclusion criteria to be eligible for entry into the trial.
-
Patient has evidence of progressive, metastatic castration-resistant disease, as defined by PCWG3 criteria.
a. Patients with de novo small cell prostate cancer are not required to have received androgen deprivation therapy (ADT).
- Progression during or following completion of at least 1 prior line of systemic therapy for locally advanced or metastatic prostate cancer.
-
Phases 2a and 2b Only:
SCNC - Cohort A of Phase 2a only:
- Patient has histologic evidence of SCNC either with archival tissue or a fresh tumor biopsy obtained during screening. Tumor biopsy tissue must be submitted for a central laboratory pathology review; however, enrollment can proceed if SCNC is determined by a local pathology review.
- Patient has previously received at least 1 prior line of cytotoxic chemotherapy. Patients who either have refused chemotherapy or are considered unsuitable for chemotherapy may be eligible following discussion with the sponsor.
- Must be willing to undergo metastatic tumor biopsy during Screening. Requirement may be waived in patients without safely accessible lesion or for patients with evaluable archival metastatic tumor tissue
- Has measurable disease per RECIST 1.1 criteria.
Adenocarcinoma - Cohort B of Phase 2a; randomized population for Phase 2b
- Patient has histologically or cytologically confirmed adenocarcinoma of the prostate without small cell neuroendocrine features.
- Patients with soft tissue disease must provide a fresh core or excisional biopsy or archival tissue from a site not previously irradiated for central pathology review; however enrollment may proceed if predominant adenocarcinoma without small cell neuroendocrine features is determined by local pathology review.
- Has been treated with at least 1 but no more than 2 second generation AR pathway target agents (e.g., abiraterone acetate and/or enzalutamide or other next generation agent) and at least 1 regimen/line of taxane containing chemotherapy in the mCSPC or mCRPC setting. Patients with known actionable mutations should have progressed on applicable standard care targeted therapy or have documented intolerance to or be unsuitable for such therapy.
- RECIST 1.1 measurable disease or detectable bone metastases by whole body bone scintigraphy.
-
Patient has serum testosterone <50 ng/dL during Screening except for those with de novo small cell prostate cancer.
a. Patients with treatment-emergent SCNC without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy except for patients with de novo small cell prostate cancer.
- Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Patient is ≥18 years of age.
- Patient's acute toxic effects of previous anticancer therapy have resolved to ≤Grade 1 except for Grade 2-3 peripheral neuropathy or any grade of alopecia.
-
Patient has adequate baseline organ function, as demonstrated by the following:
- Serum creatinine ≤1.5 times institutional upper limit of normal (ULN) or calculated creatinine clearance >50 mL/min;
- Serum albumin ≥2.5 g/dL;
- Total bilirubin ≤1.5 × ULN;
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (patients with hepatic metastases must have AST/ALT ≤5 × ULN).
-
Patient has adequate baseline hematologic function, as demonstrated by the following:
- Absolute neutrophil count (ANC) ≥1.5 × 109/L.
- Hemoglobin ≥8 g/dL and no red blood cell transfusions during the prior 14 days.
- Platelet count ≥100 × 109/L and no platelet transfusions during the prior 14 days.
-
Male patients and their female partners of childbearing potential must agree and commit to use a barrier contraception throughout the duration of the study until at least 6 months following the last dose of study drug, in addition to their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug. This criterion may be waived for male patients who have had a vasectomy >6 months before signing the informed consent form.
Exception: In the United States, female partners of study participants are not required to use contraception as a condition of their partners' eligibility, but female partners with child bearing potential should consider use of effect methods of contraception for the duration of their male partners' study participation and for at least 6 months following the last dose of study medication.
- Patient has signed informed consent prior to initiation of any study-specific procedures or treatment.
- Patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for overall survival (OS).
Exclusion Criteria:
- Patient has received treatment with >2 cytotoxic chemotherapy regimens for castration-resistant prostate cancer (CRPC). Chemotherapy in the hormone-sensitive setting does not count in this assessment provided the last dose was >6 months before study entry. A change in chemotherapy agents due to intolerance after brief exposure may not count in this assessment, pending review with Medical Monitor.
- Patient has received external-beam radiation or another systemic anticancer therapy within 14 days or 5 half-lives, whichever is shorter, prior to study treatment.
- Patient has received treatment with an investigational systemic anticancer agent within 14 days prior to study drug administration.
- Patient has received prior treatment with an anti-PD-1, anti-PD-L1, anti-programmed death ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T lymphocyte-associated antigen 4 [CTLA-4], OX-40, CD137) or requires concomitant treatment with DPP4 inhibitors.
- Patient has an additional active malignancy that may confound the assessment of the study endpoints. If the patient has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the sponsor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including transitional cell carcinoma, anal carcinoma, and melanoma in situ).
- Patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
- QT interval corrected for heart rate using Bazett's formula (QTcB) >480 msec at Screening.
- Patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study.
- Patient has brain or leptomeningeal metastases that are symptomatic and progressive on imaging. Patients with a history of central nervous system (CNS) metastases must have received appropriate treatment. Central nervous system imaging is not required prior to study entry unless there is a history of CNS involvement or clinical suspicion of CNS involvement. Imaging of patients with a prior history of CNS metastases should be compared to prior imaging to discern disease progression.
- Patient has an active autoimmune disease or Grade ≥3 non-infectious pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbimazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.
- Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of >10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 (C1D1).
- Patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, suspected or active SARS-CoV-2 (COVID-19) infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patient has known positive status for human immunodeficiency virus, active or chronic Hepatitis B, or Hepatitis C. Screening is not required.
- Patient has any medical condition which, in the opinion of the investigator, places the patient at an unacceptably high risk for toxicity.
- Any dysphagia, odynophagia, esophageal dysmotility or stricture, known GI malabsorption syndrome, or intractable diarrhea that may significantly alter the absorption of orally administered study drug.
- Patients with history of symptomatic orthostatic hypotension within 3 months prior to enrollment. Orthostatic hypotension is defined as a drop in systolic blood pressure (BP) of ≥ 20 mmHg or diastolic BP of ≥ 10 mmHg with assumption of an upright posture.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03910660
| United States, California | |
| University of California San Francisco (UCSF) | |
| San Francisco, California, United States, 94158 | |
| United States, Colorado | |
| BioXcel Clinical Research Site | |
| Denver, Colorado, United States, 80211 | |
| United States, Connecticut | |
| Yale University | |
| New Haven, Connecticut, United States, 06510 | |
| United States, Florida | |
| Moffitt Cancer Center and Research Institute | |
| Tampa, Florida, United States, 33612 | |
| United States, Michigan | |
| BioXcel Clinical Research Site | |
| Detroit, Michigan, United States, 48201 | |
| United States, New York | |
| Center for Advanced Medicine / R.J. Zuckerberg Cancer Center (Northwell Health Cancer Institute) | |
| Lake Success, New York, United States, 11042 | |
| Weill Cornell Medicine New York | |
| New York, New York, United States, 10021 | |
| White Plains Hospital Center for Cancer Care | |
| White Plains, New York, United States, 10601 | |
| United States, Ohio | |
| The Ohio State University | |
| Columbus, Ohio, United States, 43210 | |
| United Kingdom | |
| BioXcel Clinical Research Site | |
| Glasgow, England, United Kingdom, G12 0YN | |
| BioXcel Clinical Research Site | |
| London, Great Britain, United Kingdom, W1T 7HA | |
| BioXcel Clinical Research Site | |
| Sutton, Surrey, United Kingdom, SM2 5NG | |
| Study Director: | Amir Hafeez, MD | Bioxcel Therapeutics | |
| Study Chair: | Vincent O'Neill, MD | Bioxcel Therapeutics |
| Responsible Party: | BioXcel Therapeutics Inc |
| ClinicalTrials.gov Identifier: | NCT03910660 |
| Other Study ID Numbers: |
BXCL701-201 |
| First Posted: | April 10, 2019 Key Record Dates |
| Last Update Posted: | May 23, 2023 |
| Last Verified: | March 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Prostatic Neoplasms Adenocarcinoma Neuroendocrine Tumors Carcinoma, Small Cell Small Cell Lung Carcinoma Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Genital Diseases Urogenital Diseases Prostatic Diseases Male Urogenital Diseases Carcinoma |
Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Lung Diseases Respiratory Tract Diseases Pembrolizumab Antineoplastic Agents, Immunological Antineoplastic Agents |